NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses the role of next-generation sequencing in improving biomarker testing and treatment planning for solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share their insights.
- Mark Agulnik, MD, Mrinal M. Guckerman, MD, and others contribute to the discussion.
- Additional experts, such as Naval G. Daver, MD, and Jessica Altman, MD, provide their perspectives.
No direct quotes are provided in the given text.
Author's summary: NGS enhances biomarker testing for solid tumors.
More News
- Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age | PharmExec
- Following Misconduct Complaint, Supervisor Bushnell Hires Private Attorney to Challenge the County’s Investigation Process
- The AI Gender Gap Paradox (SSIR)
- Georgiana wraps up season with big win
- New Poll: Republicans, Democrats and Independents Strongly Oppose Weakening Chemical Safety Law
- The Great Tech Waltz of 2025: AI, Autonomy, and Surprises
- Airports are about to get busy with holiday travel | News Channel 3-12
- Molecular Processing Archives - Talk Business & Politics
- Waymo Co-CEO Tekedra Mawakana on What’s Next: Highways, Airports, New Cities